Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma
In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group’s dose-limiting toxicity observation period was successfully completed.
Related Articles
Support Patient Access and Education with the End Brain Cancer Initiative for GiveBIG 2025
People can help EBCI reach their goal of $20,000 dollars raised for GiveBIG 2025 by giving at endbraincancer.org/donate.
Alternating Glivec and Stivarga Doesn’t Improve Advanced GIST Outcomes
Alternating between Glivec and Stivarga therapy didn’t impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.
Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
Breast MRI helps doctors detect disease in newly diagnosed and high-risk patients without replacing mammograms, according to an expert.
How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer
I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.
RCN to recruit experts to new anti-racism subgroup | Nursing Times
Learn more about the Royal College of Nursing’s recruitment campaign to appoint four experts to an anti-racism subgroup.
TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors
Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be presented at ASCO…
Rumoured 3% pay rise proposed for nurses for 2025-26 | Nursing Times
Read about what the rumoured pay rise is for nurses and other NHS Agenda for Change staff for 2025-26, according to reports.
Zongertinib Elicits Responses in HER2-Mutant NSCLC
Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer.